Odyssey Health FY 2026: Net loss $5.73M, Diluted EPS ($0.05) — 10-K Summary

What happened

Odyssey Health reported a net loss of $5.73 million for fiscal 2026, compared with a $1.74 million loss in fiscal 2025, so the annual loss widened by $3.99 million. Diluted loss per share was $0.05, versus $0.02 a year earlier.

Confirmed

Global impact / market context

A wider loss means the company spent more than it earned, and its main products are not cleared for sale, so it has little product revenue. Management says it needs adequate funding to continue development, and without financing it may suspend research and development.

Analyst inference

Odyssey Health is a development-stage medical products company, which means its value depends on raising money and winning regulatory clearance rather than current sales. Investors would focus on its cash needs, dilution risk from raising money, and progress toward clearance.

Analyst inference

What to watch

1. Management plans to advance product development, pursue regulatory clearance and identify additional products, but only with adequate funding in place. Confirmed
2. If financing cannot be raised, the company may suspend research and development until market conditions improve, which would pause progress on CardioMap and Save-A-Life. Confirmed
3. Watch how Odyssey Health funds itself, because raising money could dilute existing shareholders, meaning each share represents a smaller ownership stake. Analyst inference

Evidence

• Original source link unavailable